Kornimate/medical-research-clean huggingface dataset:
dry needling of the trapezius muscle in office workers with neck pain

Conditions: Myofascial Trigger Point Pain

Summary: deep dry needling of active myofascial trigger points of trapezius muscle is effective in the dimminution of pain of patients

evaluation: a blind assesor does a complete evaluation of the patients to determine if they take part of the study. an assesment of pain (by visual analogue scale), pain pressure theshold (kg/cm2 by algometry, range of motion (crom goniometer in degrees) and strength (digital dinamometry in newtons) are performed. in this evaluation inclusion criteria is checked too. intervention: -treatment group(deep dry needling group (ddn)): an experienced physical therapist performed this treatment. the intervention included ddn of every active mtrp found in the trapezius muscle using a 4 cm x 0.32 mm acupuncture needle with guided tube. ). in the case of upper trapezius active mtrps, ddn was performed in the prone position. for medium and lower trapezius muscle mtrps, ddn was performed in a side-lying position as described by simons et al. (simons et al., 1999). once the needle was inserted into the mtrp previously marked by the blinded assessor, local twitch responses (ltrs) were obtained by using hong's fast-in and fast-out technique, which involves rapid movements of the needle in and out of the mtrp. after that, the stretch is performed - passive stretch of the trapezius muscle (both groups) another experienced physical therapist, after taking part of training-sesions to do the same stretch as in ddn group, performed the stretch.participants in this group received the same stretch as patients in treatment group.

Eligibility criteria:
inclusion criteria: * over 18 * present myofascial trigger points in trapezius muscle exclusion criteria: * to be under anti-inflammatory, analgesic, anticoagulant, muscle relaxant or antidepressant medication at the start of the study or one week before it (simons, 2004) * to suffer from fibromyalgia syndrome, or to have any contraindication to conservative or invasive physiotherapy (infection, fever, hypothyroidism, fear of needles, wounds in the area of the puncture, metal allergy, cancer, systemic disease) (baldry, 2005).

Keywords: myofascial pain syndromes,physiotherapy,muscle stretching exercises,neck pain,dry needling
ultrasonography and electrophysiology in gbs

Conditions: Guillain-Barre Syndrome

Summary: description of the time course of nerve ultrasonography changes in correlation to nerve conduction studies (ncs) and clinical course.

gbs is an acute- or subacute-onset polyradiculoneuropathy that often follows an upper or lower respiratory illness or gastroenteritis by 10 to 14 days. approximately 70% of patients can identify a preceding illness, although it is often benign and may be minimized or forgotten by the patient. gbs evolves over days, often beginning with numbness in the lower limbs and weakness in the same distribution. the progression of symptoms, particularly weakness, can be rapid, resulting in quadriplegia within a few days. about 50% of patients develop some degree of facial weakness. weakness attributed to other cranial nerves includes ocular dysmotility, pupillary changes, and ptosis. thirty percent of patients with gbs develop respiratory failure from phrenic nerve disease, requiring intubation and ventilation. autonomic involvement is common in gbs, with the most common manifestations being tachycardia, bradycardia, hypertension and hypotension, gastric hypomotility, and urinary retention. evidence-based research supports the use of immunotherapy for gbs; proven therapies are iv immunoglobulin (ivig) and plasma exchange, which have been shown to be equally efficacious in the management of gbs. at present, no biomarkers exist in the blood, urine, or csf that confirm the diagnosis of gbs. most patients with gbs will have an elevated csf protein, but this laboratory finding may not be present until 3 weeks after the onset of the illness. nerve conduction studies (ncs) play an important role in support gbs diagnosis and subtype classification. in the first few days of the illness, nerve conduction studies may be normal or only show subtle changes of demyelination, such as prolonged or absent f waves and h reflexes, and patchy changes in distal latencies in patients with aidp. more recently, there has been a rise in the use of peripheral nerve ultrasound (us) in the investigation of peripheral neuropathies. whilst nerve conduction studies (ncs) are helpful at providing information on the function of nerves, us is able to provide information on nerve morphology. the value of nerve ultrasonography (nus) in immune-mediated polyneuropathies is well described in the previous studies. in post-gbs patients patchy and slight enlargements have been reported. whereas in acute stage cervical spinal nerve enlargement and hypertrophy of the vagus are probably the most obvious findings. however, only little is known about the course of nerve morphology from onset until clinical recovery.

Eligibility criteria:
inclusion criteria: 1. patients newly diagnosed as guillain barre syndrome using diagnostic criteria for gbs. 2. patients from both sex and at any age group with recent onset of gbs. exclusion criteria: * patients with other possible causes of peripheral neuropathy, diabetes, renal, metabolic and others
trial of combination therapy to treat covid-19 infection

Conditions: COVID; Covid-19; Corona Virus Infection; Coronavirus Infection; Coronavirus-19; SARS-CoV2; SARS-CoV Infection

Summary: in this trial patients will be treated with either a combination of therapies to treat covid-19 or a placebo. treatment will last 10 days, and patients will be followed for 6 months.

patients in this trial will undergo treatment for 10 days with either a combination of therapies or placebo. they will then be followed for an additional 20 days.

Eligibility criteria:
inclusion criteria: 1. signed informed consent, demonstrating that the subject understands the procedures required for the study and the purpose of the study 2. healthy male or female subjects at least 18 years of age 3. diabetic and obese (bmi \> 30) patients will be included in the trial but randomization will be stratified. 4. positive test for covid-19 by rt-pcr or rapid antigen test at screening 5. subjects must agree to practice at least two highly effective methods of birth control for the duration of the study. one of these must be a barrier method. exceptions for females and partners of females that are not of childbearing potential. (e.g. surgically sterilized, post-menopausal) 6. subjects must agree they will attend the treatment facility daily for 10d in the event of failure to attend, the patient will be visited at their home to collect the nasal swab and review data. exclusion criteria: 1. refusal to sign informed consent form 2. negative test for covid-19 by rt-pcr at screening 3. severe disease symptomatically including pneumonia, respiratory distress, tachypnea, shortness of breath, temperature \> 104.0 degrees f, pleuritic pain, or frequent cough. 4. known drug allergy to any of the investigational medications 5. currently taking medication with known drug interactions with investigational medications, found in appendix ii 6. prescription or other antiviral medications 7. any comorbidities which constitute health risk for the subject including known cardiac arrhythmias - but will be limited to those on hydroxychloroquine 8. inability to attend daily for 10 days
video based mindfulness based stress reduction

Conditions: Parkinson's Disease

Summary: to evaluate the feasibility of a video based mindfulness intervention for stress reduction and to evaluate the cortisol response in persons with pd and their caregivers. the data from this project will be used for a future grant application of a stress reduction intervention in persons with pd.

participants will be enrolled at the va portland and have a baseline assessment. the baseline will assess neurological disorders (including parkinsonism) and current stress. all participants will attend 10 weeks of mindfulness based stress reduction (mbsr) through video feed on the portland va campus. during the week prior to the first class and the week after the last class, participants will complete questionnaires regarding stress, collect saliva samples, and, for the parkinson's patient, monitor motor symptoms of pd using diaries and inertial sensors. a final visit will assess stress, neurological diseases, and parkinsonism.

Eligibility criteria:
inclusion criteria: * parkinson's disease * some postural instability * tremor in upper limb * caregiver willing to also participate exclusion criteria: * no neurological disease * cognitive deficits * other neurological/psychological disorder * completion of a stress reduction program in the last 12 months

Keywords: movement disorders metabolic stress
anticipated versus actual patient and caregiver burden following ambulatory orthopedic surgery

Conditions: Stress, Psychological; Pain

Summary: in 2011, 38.6 million hospital stays occurred in the united states at a cost of $387.2 billion. 47.9 percent involved hospitalizations during which surgical procedures were performed. orthopedic procedures constituted the most frequently performed and most costly of operating room procedures. as the healthcare climate in the united states continues to change, there is a trend towards providing effective care in a fiscally conservative manner. central to this strategy is the shift towards increasing ambulatory surgical procedures from surgeries requiring post-operative admission for patients. while savings to hospitals and third-party payers are implied, there may be an unrecognized increase in financial, physical, and psychosocial post-operative costs to patients undergoing ambulatory surgery and to their caregivers. rawal et al., and mcgarth and colleagues have found that patients undergoing orthopedic procedures had moderate to severe post-operative pain. we propose to present a survey to patients and their caregivers before surgery and at multiple timepoints post-operatively to acquire information on the impacts of ambulatory orthopedic surgery. in addition to assessing post-operative pain, this study serves to examine various other possible burdens to patients that have not been previously evaluated in this patient population. references mcgarth b, elgendy h, chung f, kamming d, curti b, king s. thirty percent of patients have a moderate to severe pain 24 hr after ambulatory surgery: a survey of 5,703 patients. can j anesth. 2004; 51:886-891. rawal n, hylander j, nydahl p, olofsson i, gupta a. survey of postoperative analgesia following ambulatory surgery. acta anesthesiol scand. 1997; 41:1017-1022.


Eligibility criteria:
inclusion criteria: * patients undergoing outpatient arthroscopic knee debridement or meniscectomy surgery * age 18-85 * primary caregiver available during preoperative period who is employed full-time or part-time * english speaking * patients who are employed full-time or part-time exclusion criteria: * patients on disability or worker's compensation * patients undergoing concurrent procedures * patients who are self-employed * caregivers who are self-employed * surgeons: dr. altchek, dr. warren, dr. o'brien

Keywords: work burden ambulatory orthopedic surgery anesthesiology perioperative care
safety and efficacy of turoctocog alfa in haemophilia a subjects

Conditions: Congenital Bleeding Disorder; Haemophilia A

Summary: this trial is conducted in asia, europe, and north and south america. the trial consists of a main trial and a sub-trial. the main trial investigates safety and efficacy of turoctocog alfa (recombinant factor viii, rfviii (n8)) in haemophilia a subjects, while the sub-trial investigates safety and efficacy of turoctocog alfa in prevention and treatment of bleeding episodes during surgical procedures.


Eligibility criteria:
inclusion criteria: * male subjects with the diagnosis of severe (fviii less than or equal to 1%) haemophilia a from age 12 (except for israel where the age limit will be 18 for the first 10 subjects recruited in the trial) to 56 years having a weight of 10 to 120 kg * documented history of at least 150 exposure days to any other fviii products (prevention or treatment of bleeds) * no history of fviii inhibitors greater than or equal to 0.6 bu/ml. the inhibitor should be measured regularly for at least the last 8 years or since the first treatment of haemophilia a * no detectable inhibitors to fviii (greater than or equal to 0.6 bu/ml) (as assessed by a central laboratory at the time of screening) exclusion criteria: * congenital or acquired coagulation disorders other than haemophilia a * creatinine levels 50% above normal level (as defined by central laboratory range) * known or suspected allergy to trial product (n8) or related products
integration of vr and ar dementia prevention health education progrom for older adults with mild cognitive impairment

Conditions: Mild Cognitive Impairment (MCI); Dementia; Health Literacy; Self-Efficacy; Attitude to Health; Virtual Reality; Health Education; eHealth; Older Adults (65 Years and Older)

Summary: the goal of this randomized controlled trial is to evaluate the effectiveness of virtual reality (vr)-based cognitive health education for older adults with mild cognitive impairment (mci) in taiwan. the study aims to assess whether vr-supported interventions improve cognitive health knowledge, health literacy, and self-management skills among participants. the primary research questions are: 1. does the vr-based intervention enhance participants' knowledge related to dementia and their health literacy? 2. does the vr-based intervention improve cognitive function, mental well-being, and self-efficacy compared to a control group? participants will be randomly assigned to one of two groups: 1. intervention group: this group will receive the "vr dementia prevention health education module," an immersive virtual reality program designed to enhance dementia-related knowledge and coping strategies. 2. control group: this group will receive standard, routine health education without vr exposure.

this study is a randomized controlled trial (rct) aimed at evaluating the effectiveness of a virtual reality (vr)-based cognitive health education program for older adults in taiwan who show signs of mild cognitive impairment (mci). the research seeks to determine whether vr-enhanced dementia prevention education increases dementia-related knowledge, health literacy, self-efficacy, and acceptance of dementia compared to a control group receiving standard health education without vr exposure and intervention.

Eligibility criteria:
inclusion criteria: * adults aged 65 years and older. * ad-8 score of 2 or higher, indicating possible cognitive impairment. * ability to understand and follow basic instructions in mandarin or taiwanese. * capacity to provide informed consent or have a legally authorized representative to provide consent. * ability to tolerate and interact with vr equipment (e.g., wearing a vr headset, using hand controllers). exclusion criteria: * diagnosed with moderate to severe dementia (i.e., unable to follow basic instructions). * presence of severe visual, auditory, or motor impairments that hinder interaction with vr devices. * diagnosed with severe psychiatric disorders (e.g., schizophrenia, major depressive disorder). * unable to communicate effectively in mandarin or taiwanese.
dornase alfa administered to patients with covid-19 (dacovid)

Conditions: COVID-19; Mechanical Ventilation

Summary: mechanically ventilated patients with coronavirus disease 2019 (covid-19) have a mortality of 24-53%, in part due to distal mucopurulent secretions interfering with ventilation. dornase alfa is recombinant human dnase 1 and digests dna in mucoid sputum. nebulized dornase alfa is fda-approved for cystic fibrosis treatment. dna from neutrophil extracellular traps (nets) contributes to the viscosity of mucopurulent secretions. nets are found in the serum of patients with severe covid-19, and targeting nets reduces mortality in animal models of acute respiratory distress syndrome (ards). thus, dornase alfa may be beneficial to patients with severe covid-19-acting as a mucolytic and targeting nets.

demographic, clinical data, and outcomes were collected from the electronic medical records of five mechanically ventilated patients with covid-19-including three requiring veno-venous extracorporeal membrane oxygenation (vv-ecmo)-treated with nebulized in-line endotracheal dornase alfa co-administered with albuterol (used to increase delivery to the alveoli), between march 31 and april 24, 2020. data on tolerability and responses, including longitudinal values capturing respiratory function and inflammatory status, were analyzed.

Eligibility criteria:
inclusion criteria: * mechanically ventilated patients with covid-19 exclusion criteria: * healthy, non-ventilated
outcomes of intra-cytoplasmic sperm injection in infertile men with non-tense vaginal hydrocele

Conditions: Infertility, Male

Summary: infertile men due to oligoasthenospermia with non-tense hydroceles are subjected to icsi

sixty male infertile patients with oligoasthenospermia were recruited from outpatient clinic of urology department, tanta university. patients were selected according to inclusion and exclusion criteria. the inclusion criteria were: (a) infertile couples due to male factor (b) oligoasthenospermia (c) normal hormonal profile (serum free and total testosterone, prolactin, estrogen and lh), (d) presence or absence of non-tense vaginal hydrocel. the exclusion criteria were: (a) presence of varicocele, (b) history of recent testicular trauma, (c) history of recent or old testicular inflammation, (d) tense vaginal hydrocele and (e) presence of potential female pathologies. sample size calculation: with h0 denoting higher success rates for icsi in absence of non-tense hydrocele and confidence level of 95% and interval of 5 the sample size was 30. the program used was epi info 0.7. randomization and allocation: enrolled patients were randomly allocated into 2 groups. the first group (n=30) who have oligoasthenospermia with non-tense vaginal hydrocele (study group) and the second group (n=30) who have oligoasthenospermia with no hydrocele group (control group). randomization was done by computer-generated serial numbers where each number was enveloped. each number denotes a certain allocation group. allocation was by alternate method and envelope opening did not change allocation. methods: males were assessed by genital examination, ultrasound and scrotal doppler. female partners were given long agonist stimulation protocols, ovum pickup fertilization by sperms and then embryo transfer on day 5. demographic data of both couples, duration of infertility, seminal parameters (who-2010) and results of icsi in these couples were recorded.

Eligibility criteria:
inclusion criteria: * infertile couples due to male factor * oligoasthenospermia * normal hormonal profile (serum free and total testosterone, prolactin, estrogen and lh) * presence or absence of non-tense vaginal hydrocele exclusion criteria: * presence of varicocele * history of recent testicular trauma * history of recent or old testicular inflammation * tense vaginal hydrocele * presence of potential female pathology

Keywords: infertility male factor infertility oligoasthenospermia vaginal hydrocele
safety & effectiveness of tovinontrine in chronic heart failure with preserved ejection fraction (cycle-2-pef)

Conditions: Heart Failure; Heart Failure Preserved Ejection Fraction; Cardiovascular Diseases; Heart Diseases

Summary: the purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower nt-probnp in patients with chronic heart failure with preserved ejection fraction


Eligibility criteria:
inclusion criteria: * is an adult male or female patient ≥ 18 years of age * has evidence in the medical history supporting a diagnosis of clinical hf syndrome, nyha functional class ii to iii, with the duration of at least 6 months prior to the time of screening. the hf syndrome is defined by documentation of 1 or more of the following: * at least 1 of the typical symptoms due to hf such as dyspnea and/or fatigue limiting exercise capacity; * at least 1 of the typical signs of hf such as peripheral edema, elevated jugular venous pressure, pulmonary crackles; or * hospitalization, emergency department visit, or outpatient visit for hf requiring intravenous (iv) or subcutaneous (sq) diuresis within the past 12 months. * has ejection fraction (ef) \>40% and left atrial enlargement by transthoracic echocardiogram (tte) performed and interpreted locally at the time of screening; * has nt-probnp level ≥ 300 pg/ml at the time of screening. patients with atrial fibrillation or flutter at the time of screening are required to have an nt probnp level of ≥500 pg/ml at the time of screening; * is on stable optimized doses of guideline-directed hf therapy, per investigator's clinical judgment, for a minimum of 4 weeks prior to the time of screening and during the screening period, with no planned changes after randomization; has had no addition of new guideline-directed hf therapy within the 3 months prior to the time of screening or during the screening period; exclusion criteria: * has documented ef ≥ 60% by tte within 6 months of the time of screening or during the screening period; * has evidence of recent hf exacerbation defined by hospitalization or requirement for iv or sq diuretics within 60 days of the time of screening or during the screening period; * has a requirement for routine, scheduled outpatient iv infusions for hf (ie, inotropes, vasodilators, or diuretics) or routinely scheduled ultrafiltration; * has elective interventions (eg, percutaneous coronary intervention, device implantations, percutaneous structural heart disease interventions, cardiac and non-cardiac surgery) planned to occur during involvement in this study; * has acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery, or carotid angioplasty within 60 days of the time of screening or during the screening period; * has had a prior or planned orthotopic heart transplantation; * has presence of or plan for mechanical circulatory support; note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: pde9 ped9 inhibitor heart failure crd-750 tovinontrine hfpef